ReviewRheumatology (Oxford, England)2019
Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.
Review in Rheumatology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.Clinical rheumatology · 2021Pooled it
- Rituximab-induced Acute Thrombocytopenia in Systemic Sclerosis: A Case Report of Two Cases.Internal medicine (Tokyo, Japan) · 2026Article
- The value of serum biomarkers in the management of interstitial lung disease in patients with connective tissue disease: a protocol for an observational study.Journal of thoracic disease · 2026Article
- Simultaneous onset of systemic sclerosis and light chain amyloidosis: the first report of a case report and review of the literature.Rheumatology international · 2025Review
- Mitochondrial DNA Sensing Pathogen Recognition Receptors in Systemic Sclerosis Associated Interstitial Lung Disease: A Review.Current treatment options in rheumatology · 2023Article
- Diagnosis of interstitial lung disease (ILD) secondary to systemic sclerosis (SSc) and rheumatoid arthritis (RA) and identification of 'progressive pulmonary fibrosis' using chest CT: a narrative review.Clinical and experimental medicine · 2023Review
- Clinical phenotype in scleroderma patients based on autoantibodies.Rheumatology advances in practice · 2023Article
- Cross-cultural validation of the Chinese version of the EmPHasis-10 questionnaire in connective tissue disease patients with pulmonary arterial hypertension and its relationship with risk stratification.BMC pulmonary medicine · 2022Article
- Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis.The European respiratory journal · 2022Article
- Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease.Biomedicines · 2022Review
- [Modern drug therapy for systemic sclerosis associated interstitial lung disease].Deutsche medizinische Wochenschrift (1946) · 2022Article
- Management of Connective Tissue Disease-related Interstitial Lung Disease.Current pulmonology reports · 2022Review
- Article
- Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.Rheumatology international · 2021Review
- Distinct Metalloproteinase Expression and Functions in Systemic Sclerosis and Fibrosis: What We Know and the Potential for Intervention.Frontiers in physiology · 2021Review
- Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.Respirology (Carlton, Vic.) · 2021Article
- Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.Frontiers in immunology · 2021Review
- Evolution ofInternational journal of molecular sciences · 2020Review
- Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2020Article
- The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center.Clinical rheumatology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is becoming the most commonly used medication in clinical practice in North America and the UK, but its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell-cell and cell-extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life. Here we review ongoing trials of established and novel agents that are currently recruiting patients with SSc-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.